Safety questions over the lung drug Spiriva, marketed by Pfizer Inc and Germany's Boehringer Ingelheim, may arouse a great demand for GlaxoSmithKline Plc's top-seller Advair, according to industry analysts.
The U.S. Food and Drug Administration said late on Tuesday that a meta-analysis of past clinical trials showed Spiriva may increase the risk of stroke, although the risk assessment was not yet conclusive.
Spiriva is used to treat chronic obstructive pulmonary disease, or COPD. Advair is also given for COPD but is typically used second line, once the condition progresses after Spiriva treatment.
"Potential safety concerns over Spiriva could facilitate earlier Advair use in less severe patients," Morgan Stanley analysts wrote in a note.
However, Spiriva is not expected to be pulled from the market and the brokerage said the worst-case scenario for the product was probably a "black box" warning in its labelling. Advair has also suffered from safety problems in the past, which have hit the drug's growth in the asthma-treatment market.
Chronic Obstructive Pulmonary Disease (COPD), also known as chronic obstructive airway diseases (COAD), is a group of diseases characterized by the pathological limitation of airflow in the airway that is not fully reversible. COPD is the umbrella term for chronic bronchitis, emphysema and a range of other lung disorders. It is most often due to tobacco smoking, but can be due to other airborne irritants such as solvents, as well as congenital conditions such as alpha-1-antitrypsin deficiency. It is the 4th leading cause of death in the U.S.
The discovery of the submarine has unveiled a few "inconsistencies." For example, how can one explain the fact that the sub was found where it needed to be searched for from the start?
When on a state visit to Singapore, Russian President Vladimir Putin promised to revisit the discussion of the 1956 Declaration between the USSR and Japan regarding the issue of the peace treaty with Japan
The TurkStream, which runs along the bottom of the Black Sea from Russia's Anapa to Turkey, will consist of two lines, each with a capacity of 15.75 billion cubic meters of gas a year